| domain | established finding | suggested ontology identifiers/terms | evidence strength/limitations |
|---|---|---|---|
| Disease identity | Tyrosinemia type III is an ultra-rare inborn error of tyrosine metabolism caused by deficiency of 4-hydroxyphenylpyruvate dioxygenase; recognized disease identifiers include MONDO:0010162, OMIM:276710, Orphanet:69723 (pqac-00000006, pqac-00000012) | MONDO:0010162; OMIM:276710; Orphanet:69723; suggested label synonym: “4-hydroxyphenylpyruvate dioxygenase deficiency” | Strong for identifiers/disease concept from curated resources and review; rarity means phenotype boundaries remain incompletely defined (pqac-00000006, pqac-00000012) |
| Synonyms | Reported names include tyrosinemia type III, tyrosinemia type 3, hereditary hypertyrosinemia type III, and 4-hydroxyphenylpyruvate dioxygenase deficiency (pqac-00000001, pqac-00000008) | Suggested synonyms only; exact ontology synonym set should be verified in MONDO/Orphanet | Moderate; terminology varies across case reports and older literature (pqac-00000001, pqac-00000008) |
| Etiology/gene | Causal gene is HPD, encoding 4-hydroxyphenylpyruvate dioxygenase, in the tyrosine catabolic pathway (pqac-00000006, pqac-00000007, pqac-00000018) | HPD (HGNC symbol); suggested functional term: loss of function/absent or deficient HPD activity; suggested pathway: tyrosine catabolic process | Strong for gene-disease link, including ClinGen-definitive curation noted in Open Targets-linked evidence; variant-level functional data are sparse for many alleles (pqac-00000006) |
| Inheritance | Autosomal recessive inheritance with biallelic HPD variants (pqac-00000001, pqac-00000004, pqac-00000006, pqac-00000012) | Suggested inheritance term: autosomal recessive inheritance [HPO term suggested, exact ID not confirmed here] | Strong for inheritance; penetrance/expressivity remain uncertain because some patients are asymptomatic (pqac-00000009, pqac-00000014) |
| Molecular defect | HPD normally converts 4-hydroxyphenylpyruvate to homogentisate; deficiency blocks this step and causes accumulation of upstream tyrosine-related metabolites without the toxic downstream metabolites typical of type I disease (pqac-00000003, pqac-00000007, pqac-00000018) | Suggested GO term: tyrosine catabolic process; suggested CHEBI terms: L-tyrosine, 4-hydroxyphenylpyruvate, homogentisate | Strong for pathway position; downstream neurotoxicity mechanism in humans remains unresolved (pqac-00000003, pqac-00000018) |
| Pathogenic variants | Review of published patients found 11 HPPD/HPD variants in 16 patients by 2022: 7 missense, 2 nonsense, 1 splice-site, 1 frameshift; recurrent p.Tyr160Cys reported in 2 families; later 2023 case added compound heterozygous p.W25Ter and p.T138M (pqac-00000009, pqac-00000014, pqac-00000004) | Suggested sequence consequence terms: missense variant, nonsense variant, splice donor/acceptor variant, frameshift variant | Moderate-strong for published spectrum; many are private variants and genotype-phenotype correlation is not established (pqac-00000009, pqac-00000014) |
| Core biochemical phenotype | Elevated blood/serum tyrosine with increased urinary excretion of 4-hydroxyphenylpyruvate, 4-hydroxyphenyllactate, and 4-hydroxyphenylacetate/related p-hydroxyphenyl derivatives is characteristic (pqac-00000001, pqac-00000002, pqac-00000005, pqac-00000020) | Suggested HPO: Hypertyrosinemia [exact ID not confirmed]; suggested lab terms: increased urinary 4-hydroxyphenylpyruvate, increased urinary 4-hydroxyphenyllactate, increased urinary 4-hydroxyphenylacetate | Strong for biochemical signature; exact analyte nomenclature varies by report (pqac-00000001, pqac-00000020) |
| Typical tyrosine levels | Reported blood tyrosine values are often ~350–650 μmol/L; examples include 425–535 μmol/L in an asymptomatic girl and 709 μmol/L neonatally in a 2023 Iranian case (pqac-00000001, pqac-00000002, pqac-00000004) | Suggested quantitative lab annotation rather than ontology term | Moderate; based on small case series/case reports with assay/reference-range variation (pqac-00000001, pqac-00000004) |
| Neurologic phenotypes | Neurologic manifestations reported across cases include developmental delay/psychomotor retardation, intellectual disability/mental retardation, seizures/convulsions, ataxia, and autism; however, some genetically confirmed individuals are asymptomatic (pqac-00000001, pqac-00000002, pqac-00000005, pqac-00000009) | Suggested HPO terms: Developmental delay; Psychomotor retardation; Intellectual disability; Seizure; Ataxia; Autistic behavior [exact IDs not confirmed here] | Moderate; recurrently reported but case numbers are tiny and causality of neurologic findings versus ascertainment bias remains debated (pqac-00000001, pqac-00000020) |
| Asymptomatic presentation | A substantial minority of published patients were asymptomatic despite persistent biochemical abnormalities; 5 of 16 patients in the 2022 review were asymptomatic (pqac-00000001, pqac-00000003, pqac-00000009, pqac-00000014) | Suggested phenotype annotation: asymptomatic hypertyrosinemia [suggestion only] | Strong for existence of asymptomatic cases; weak for predicting who will remain asymptomatic long term (pqac-00000009, pqac-00000014) |
| Renal phenotype | Classical liver and kidney dysfunction are generally absent, but recurrent proteinuria has been reported in at least one asymptomatic patient and increased propensity for proteinuria has been noted (pqac-00000003, pqac-00000004) | Suggested HPO: Proteinuria [exact ID not confirmed] | Weak-moderate; renal involvement is not a consistent core feature and is based on limited case-level evidence (pqac-00000003, pqac-00000004) |
| Hepatic phenotype | Unlike tyrosinemia type I, hepatocellular injury is typically absent; reports emphasize no liver damage as a distinguishing feature, though isolated neonatal hepatitis has been described in a 2023 case report (pqac-00000002, pqac-00000004, pqac-00000005) | Suggested differential annotation rather than core phenotype; UBERON suggestion: liver | Moderate; absence of hepatic disease is a useful differentiator, but occasional hepatic presentations may reflect ascertainment complexity or comorbidity (pqac-00000004) |
| Anatomy/organs | Main tissues relevant to disease biology are liver and kidney, where HPD is mainly expressed; nervous system/brain involvement is implicated clinically by neurologic symptoms (pqac-00000007, pqac-00000012) | Suggested UBERON: liver, kidney, brain; suggested body systems: metabolic, nervous | Strong for organ expression/pathway anatomy; direct tissue pathology data in humans are sparse (pqac-00000007, pqac-00000012) |
| Cell types | Human mechanistic literature suggests hepatocytes as primary metabolic cell type; neurons are implicated by neurologic phenotype; one paper also discusses neutrophils/neurons in relation to nitric oxide release, but this is limited evidence (pqac-00000016) | Suggested CL terms: hepatocyte, neuron; suggested CL term: neutrophil (exploratory) | Moderate for hepatocyte/neuron; weak for neutrophil relevance to disease mechanism (pqac-00000016) |
| Subcellular compartments | Disease mechanism involves enzyme deficiency in metabolic pathways; a mouse/mechanistic study identified regulation of HPD protein stability through phosphorylation, ubiquitination, and proteasomal degradation (TTC36-STK33-PELI1 axis) (pqac-00000018, pqac-00000019) | Suggested GO cellular component terms: cytosol/cytoplasm, proteasome complex; suggested process terms: protein ubiquitination, proteasomal protein catabolic process | Moderate for HPD regulation biology, but this evidence is mainly experimental/model-based and not specific to human inherited alleles (pqac-00000018, pqac-00000019) |
| Diagnosis | Diagnostic approach relies on metabolic screening showing elevated tyrosine plus urinary p-hydroxyphenyl metabolites, followed by molecular confirmation of biallelic HPD variants by targeted sequencing, gene panel, WES, or Sanger confirmation (pqac-00000001, pqac-00000002, pqac-00000004, pqac-00000020) | Suggested diagnostic categories: plasma amino acids, urine organic acids, molecular genetic testing | Strong for core diagnostic workflow; no universally standardized diagnostic criteria specific to type III were identified (pqac-00000020) |
| Differential diagnosis | Important differentials include tyrosinemia type I, tyrosinemia type II, transient neonatal tyrosinemia, and hawkinsinuria; type III differs from type I by lack of succinylacetone accumulation/hepatorenal disease and from type II by generally lower tyrosine levels and absence of corneal/skin disease (pqac-00000003, pqac-00000008, pqac-00000020) | Suggested related disease mappings: tyrosinemia type I, tyrosinemia type II, hawkinsinuria, transient neonatal tyrosinemia [exact ontology IDs not confirmed] | Moderate; differential framework is well supported in reviews, but formal criteria are not standardized for this ultra-rare disorder (pqac-00000020) |
| Newborn screening | Type III can be detected after elevated tyrosine on newborn screening, but routine screening specificity is limited because tyrosine elevation is nonspecific; published cases include neonatal-screen-detected patients, while some regions report no dedicated HT3 screening program (pqac-00000003, pqac-00000015, pqac-00000016) | Suggested screening annotation: elevated tyrosine on tandem MS/MS newborn screening | Moderate; real-world implementation exists indirectly through tyrosine elevation, but population screening performance metrics for HT3 are not established here (pqac-00000015, pqac-00000016) |
| Treatment | Main reported treatment is dietary restriction of tyrosine and phenylalanine; one review cites ascorbic acid supplementation (50 mg/day) with normalization of tyrosine and improvement of seizures in a case; some asymptomatic patients were not treated and remained well (pqac-00000001, pqac-00000002, pqac-00000016, pqac-00000020) | Suggested NCIT intervention terms: Dietary modification; Low phenylalanine diet; Low tyrosine diet; Ascorbic acid supplementation | Moderate; evidence is based on case reports/experience only, and benefit for long-term neuroprotection is uncertain (pqac-00000020) |
| Monitoring/outcomes | Follow-up generally centers on plasma tyrosine, urinary metabolites, neurologic/developmental assessment, and growth; outcomes are variable, with some patients improving on diet and others remaining asymptomatic without clear progression (pqac-00000001, pqac-00000016, pqac-00000020) | Suggested monitoring concepts: plasma tyrosine, urine organic acids, developmental assessment | Weak-moderate; no formal longitudinal natural-history dataset or validated outcome measures were identified (pqac-00000016, pqac-00000020) |
| Epidemiology | Ultra-rare disorder: only 13 cases were noted by 2015, 16 patients by the 2022 variant review, and about 18 cases cited in a 2023 case report; no robust prevalence or incidence estimates were identified (pqac-00000001, pqac-00000009, pqac-00000016) | Suggested epidemiology annotation: ultra-rare Mendelian disease | Moderate for approximate published case counts; weak for true prevalence/incidence because underdiagnosis is likely (pqac-00000003, pqac-00000009) |
| Population distribution | Reported patients/variants have come from Europe and parts of Asia, including Portugal, Turkey, Sweden, Poland, Japan, Iran, and China; no data were noted from North/Central America, Africa, Australia, or Oceania in the 2022 review (pqac-00000009, pqac-00000014) | Suggested demographic annotation only; no founder effect established for type III | Moderate for published geographic distribution; reflects publication bias rather than true population risk (pqac-00000009, pqac-00000014) |
| Modifier/protective factors | No validated genetic protective variants, modifier genes, or environmental protective factors specific to human HT3 were identified; genotype-phenotype correlation remains unclear (pqac-00000009, pqac-00000014) | None established; leave ontology mapping blank/NA | Weak due to lack of evidence (pqac-00000009, pqac-00000014) |
| Prevention/genetic counseling | Primary prevention is not established; secondary prevention may occur through newborn screening flagging elevated tyrosine; tertiary prevention is dietary/metabolic management. Carrier testing, family screening, and prenatal testing are plausible for known familial HPD variants, but disease-specific protocols were not well detailed in retrieved evidence (pqac-00000004, pqac-00000015) | Suggested counseling concepts: carrier testing, cascade testing, prenatal diagnosis [suggestions only] | Weak-moderate; inferred from Mendelian genetics and review conclusions rather than disease-specific prospective studies (pqac-00000015) |
| Human evidence quality | Evidence base is dominated by case reports, small series, and reviews; 2022 review explicitly states genotype-phenotype correlation cannot be clearly concluded due to small numbers and private mutations (pqac-00000009, pqac-00000014) | Evidence tag suggestion: human clinical case report/series | Strong statement about limitation; this constrains confidence in prognosis and management recommendations (pqac-00000014) |
| Animal/models | HPD-deficient mice model hypertyrosinemia with elevated tyrosine and urinary metabolites, and generally lack the severe visceral injury seen in type I; newer mechanistic mouse work links reduced hepatic HPD to tyrosinemia and hippocampal neuron injury via TTC36-STK33-PELI1 regulation. Drosophila nutrigenomics work lists tyrosinemia type III among amino-acid-disorder models/platform efforts (pqac-00000007, pqac-00000018, pqac-00000010, pqac-00000011) | Suggested model annotations: mouse knockout model; Drosophila disease model/platform | Moderate for mechanistic utility; mouse neurologic findings may not map directly to human HT3 clinical variability (pqac-00000018) |


*Table: This table provides a compact, ontology-ready summary of Tyrosinemia type III, covering identifiers, genetics, biochemical and clinical features, anatomy, diagnosis, treatment, epidemiology, and model systems. It emphasizes where evidence is strong versus where the ultra-rare nature of the disease leaves major gaps.*